Therefore, we tested the effects of combining SAS and APR-246 for the treatment of breast cancer cell lines harboring different TP53 states in vitro, demonstrating that their combination was more effective than the single treatments in reducing cancer cell viability, inducing apoptosis, and affecting cancer stem cell (CSC) self-renewal. Here, TP53 is linked to cancer.